UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

————

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): March 4, 2011

TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-34473

20-2533768

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification Number)

4101 Research Commons
79 T.W. Alexander Drive

Research Triangle Park, North Carolina 27709

(Address of principal executive offices)

(919) 316-6300

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01. other events.

On March 4, 2011, Talecris Biotherapeutics Holdings Corp. (“Talecris”) and Grifols, S.A. (“Grifols”) jointly announced that the “outside date” of their pending merger transaction has been extended to June 30, 2011 (from March 6, 2011) and that Grifols had extended the financing and financing commitments from its lenders to June 30, as well. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibits to this Form 8-K

Exhibit No.	Description
99.1	Press Release, dated March 4, 2011

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Talecris Biotherapeutics Holdings Corp.
(Registrant)

Date: March 4, 2011

/s/ John F. Gaither, Jr.

Name: John F. Gaither, Jr.
Title: Executive Vice President, General Counsel

and Corporate Secretary

EXHIBIT INDEX

Exhibits to this Form 8-K

Exhibit No.	Description
99.1	Press Release, dated March 4, 2011

Talecris Biotherapeutics Holdings Corp. 8-K